Human melanoma therapy in the SCID mouse: In vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments

International Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 486-493

  Cochlovius, Björn ^a   Perschl, Astrid ^a   Adema, Gosse J ^b   Zöller, Margot ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; COMBINED IMMUNODEFICIENCY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNE RESPONSE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; ANTIBODIES, BISPECIFIC; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, SCID; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032916662     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990505)81:3<486::AID-IJC25>3.0.CO;2-P     Document Type: Article

References (30)

1. ARNOLD, B., HORSTMANN, U., KUON, W., BURGERT, H.G., HÄMMERLING, G. and KVIST, S., Alloreactive cytolytic T cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens. Proc. nat. Acad. Sci. (Wash.), 82, 7030-7037 (1985).
2. BAKKER, A.B., SCHREURS, M.W., DE BOER, A.J., KAWAKAMI, Y., ROSENBERG, S.A., ADEMA, G.J. and FIGDOR, C.G., Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. exp. Med., 179, 1005-1009 (1994).
3. BECKER, J.C., PANCOOK, J.D., GILLIES, S.D., FURUKAWA, K. and REISFELD, R.A., T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. exp. Med., 183, 2361-2366 (1996).
4. BOLHUIS, R.L., HOOGENBOOM, H.R. and GRATAMA, J.W., Targeting of peripheral blood T lymphocytes. Springer Semin. Immunopathol., 18, 211-226 (1996).
5. BOON, T., CEROTTINI, J.C., VAN DEN EYNDE, B., VAN DER BRUGGEN, P. and VAN PEL, A., Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol., 12, 337-365 (1994).
6. CELIS, E., SETTE, A. and GREY, H.M., Epitope selection and development of peptide based vaccines to treat cancer. Semin. Cancer Biol., 6, 329-336 (1995).
7. + T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function. J. Immunother., 20, 101-110 (1997).
8. ECONOMOU, J.S. and 12 OTHERS, In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J. clin. Invest., 97, 515-521 (1996).
9. FLEUREN, G.J., GORTER, A., KUPPEN, P.J., LITVINOV, S. and WARNAAR, S.O., Tumor heterogeneity and immunotherapy of cancer. Immunol. Rev., 145, 91-122 (1995).
10. GUO, Y.J., CHE, X.Y., SHEN, F., XIE, T.P., MA, J., WANG, X.N., WU, S.G., ANTHONY, D.D. and WU, M.C., Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nature Med., 3, 451-455 (1997).
11. HARUTA, I., YAMAUCHI, K., ARUGA, A., KOMATSU, T., TAKASAKI, K., HAYASHI, N. and HANYU, F., Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK-cell and CTL therapy. J. Immunother., 19, 218-223 (1996).
12. HOSKEN, N.A. and BEVAN, M.J., Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science. 248, 367-369 (1991).
13. JUNG, G., FREIMANN, U., VON MARSCHALL, Z., REISFELD, R.A. and WILMANN, W., Target cell-induced T cell activation with bi-and trispecific antibody fragments. Europ. J. Immunol., 21, 2431-2435 (1991).
14. KAWAKAMI, Y. and ROSENBERG, S.A., Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol., 14, 173-192 (1997).
15. MAEURER, M.J., STORKUS, W.J., KIRKWOOD, J.M. and LOTZE, M.T., New treatment options for patients with melanoma: a review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6, 11-24 (1996).
16. MATZINGER, P., The JAM test. A simple assay for DNA fragmentation and cell death. J. immunol. Meth., 145, 185-192 (1991).
17. MATZKU, S., BROCKER, E.B., BRUGGEN, J., DIPPOLD, W.G. and TILGEN, W., Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res., 46, 3848-3854 (1986).
18. MULE, J.J., JICHA, D.L. and ROSENBERG, S.A., The use of congenitally immunodeficient mice to study human tumor metastases and immunotherapy. J. Immunother., 12, 196-198 (1992).
19. NAKAJIMA, F., KHANNA, A., XU, G., LAGMAN, M., HASCHEMEYER, R., MOURADIAN, J., WANG, J.C., STENZEL, K.H., RUBIN, A.L. and SUTHANTHIRAN, M., Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc. nat. Acad. Sci. (Wash.). 91, 7889-7893 (1994).
20. PARKHURST, M.R., SALGALLER, M.L., SOUTHWOOD, S., ROBBINS, P.F., SETTE, A., ROSENBERG, S.A. and KAWAKAMI, Y., Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157, 2539-2548 (1996).
21. PARMIANI, G. and COLOMBO, M.P., Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res., 5, 295-301 (1995).
22. RENNER, C., JUNG, W., SAHIN, U., DENFELD, R., POHL, C., TRÜMPER, L., HARTMANN, F., DIEHL, V., VAN LIER, R. and PFREUNDSCHUH, M., Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science, 264, 833-835 (1994).
23. RIEDLE, S., RÖSEL, M. and ZÖLLER, M., In vivo activation and expansion of T cells by a bispecitic antibody abolishes metastasis formation and reduces tumor takes of human melanoma cells in SCID mice. Int. J. Cancer. 75, 908-918 (1997).
24. ROSENBERG, S.A., The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Ann. Rev. Med., 47, 481-491 (1996).
25. SHPITZ, B., FERNANDES, B.J., MULLEN, J.B., RODER, J.C. and GALLINGER, S., Improved engraftment of human tumours in SCID mice pretreated with radiation and anti-asialo GM1. Anticancer Res., 14, 1927-1934 (1994).
26. SONDEL, P.M., HANK, J.A., KOHLER, P.C., SOSMAN, J.A., WEIL-HILLMAN, G. and FISCH, P., The cellular immunotherapy of cancer: current and potential use of interleukin-2. Crit. Rev. Oncol. Hematol., 9, 125-147 (1989).
27. THIELEMANS, K.M., Immunotherapy with bispecific antibodies. Verh. K. Acad. Geneeskd. Belg., 57, 229-247 (1995).
28. VAN MUIJEN, G.N.P., CORNELISSEN, L.M.A.H., JANSEN, C.F.J., FIGDOR, C.G., JOHNSON, J.P., BRÖCKER, E.B. and RUITER, D.J., Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin. exp. Metast., 9, 259-272 (1991).
29. XU, H., KRÄMER, M., SPENGLER, H.P. and PETERS, J.H., Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells. Advance. exp. Med. Biol., 378, 75-78 (1995).
30. ZAROUR, H., DE SMET, C., LEHMANN, F., MARCHAND, M., LETHE, B., ROMERO, P., BOON, T. and RENAULD, J.C., The majority of autologous cytolytic-T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide from gene Pmell7/ gp100. J. invest. Dermatol., 107, 63-67 (1996).